<DOC>
	<DOCNO>NCT00980629</DOCNO>
	<brief_summary>This study investigate efficacy safety M516102 evaluate dose response relationship M516102 placebo , treatment pruritus associate atopic dermatitis .</brief_summary>
	<brief_title>Dose-Finding Study M516102 Treatment Pruritus Associated With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<criteria>1 . Male female patient ( age 1865 year ) diagnosis AD . 2 . Female patient child bear potential must use medically acceptable form contraception . 3 . Patients able willing give sign informed consent . 4 . Patients pruritus exceed reference range . 1 . Patients history allergy hydrocortisone . 2 . Patients history relevant drug hypersensitivity . 3 . Patients history contact dermatitis induce topical steroid . 4 . Patients take , unwilling take , medication therapy prohibit protocol complete duration study . 5 . Patients history presence cancer . 6 . Patients renal liver insufficiency , clinically significant cardiac , renal hepatic disease . 7 . Patients , opinion investigator , deem eligible determined medical history , physical examination clinical laboratory safety test . 8 . Patients pruritus associate condition AD . 9 . Patients pruritus face head . 10 . Patients , opinion investigator , clinically relevant history presence disease , surgical history AD likely affect conduct study . 11 . Patients use M5161 ( active ingredient M516102 ) . 12 . Patients communicate reliably investigator . 13 . Patients pregnant lactate . 14 . Patients use IMP and/or participate clinical trial within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>